| Identification | More | [Name]
Danofloxacin mesylate | [CAS]
119478-55-6 | [Synonyms]
1-cyclopropyl-6-fluoro-7-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid monomethanesulfonate
DANOFLOXACIN MESILATE
DANOFLOXACIN MESULATE
DANOFLOXACIN MESYLATE
DANOFLOXANCIN MESYLATE
Nofloxacin
Advoci
CP-76136-27
Danofloxacin Methanesulfonate
1-Cyclopropyl-6-fluoro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid monomethanesulfonate
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4-oxo-3-Quinolinecarboxylic Acid Mesylate
Dafloxacin mesylate | [EINECS(EC#)]
638-813-3 | [Molecular Formula]
C20H24FN3O6S | [MDL Number]
MFCD00673687 | [Molecular Weight]
453.48 | [MOL File]
119478-55-6.mol |
| Chemical Properties | Back Directory | [Appearance]
Crystalline Solid | [Melting point ]
337-339°C | [storage temp. ]
0-6°C | [solubility ]
Aqueous Base (Slightly, Sonicated), DMSO (Slightly, Sonicated) | [form ]
Solid | [color ]
White to Off-White | [Usage]
Fluorinated quinolone antibacterial | [Stability:]
Hygroscopic | [CAS DataBase Reference]
119478-55-6(CAS DataBase Reference) |
| Questions And Answer | Back Directory | [Description]
Danofloxacin is a fluoroquinolone antibiotic and a type II topoisomerase inhibitor. It has a broad antimicrobial spectrum. It can be used as an anti-infective agent for veterinary use only.
| [Brand Name(s) in US]
Advocin
| [Reference]
J. A. Schrickx, J. Fink-Gremmels, Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters, British Journal of Pharmacology, 2009, vol. 150, pp. 463-469
|
| Hazard Information | Back Directory | [Chemical Properties]
Crystalline Solid | [Uses]
Danofloxacin is a fluoroquinolone antibacterial for veterinary use, with MIC90 of 0.28 μM | [Uses]
Fluorinated quinolone antibacterial | [Definition]
ChEBI: Danofloxacin mesylate is a member of quinolines. | [Veterinary Drugs and Treatments]
Danofloxacin mesylate injection is indicated for the treatment of
Bovine Respiratory Disease (BRD) associated with Mannheimia
(Pasturella) hemolytica and P. multocida in cattle (not dairy or
veal). Because of the drug’s spectrum of activity, it may also be of
benefit in the treatment of infections caused by Histophilus somni
(Haemophilus somnus) or M. bovis, but the drug is not labeled (at
the time of writing) for treating these pathogens. In other countries,
danofloxacin may be labeled for use in swine and chickens
(non-laying), but in the USA it is illegal to use the drug in an extralabel
manner in food-producing species.
Danofloxacin may be of benefit in treating susceptible infections in
adult horses, camelids and other non-food producing species. |
|
|